Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biofrontera ( (BFRI) ) just unveiled an update.
On June 12, 2025, Biofrontera Inc. held its Annual Meeting of Stockholders, where key decisions were made to shape the company’s future. Stockholders elected Heikki Lanckriet as a Class I director, approved an increase in authorized common stock shares, agreed to adjourn the meeting if necessary for further proxy solicitation, and ratified the appointment of CBIZ CPAs P.C. as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to enhance Biofrontera’s operational capabilities and strategic positioning in the biotechnology sector.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s stock score reflects financial difficulties, highlighted by negative cash flows and net losses, compounded by regulatory compliance challenges. While there are positive strides in revenue and cost management, these are overshadowed by serious financial and market compliance concerns.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. operates in the biotechnology industry, focusing on the development and commercialization of dermatological products. The company primarily targets the treatment of skin diseases, offering innovative medical solutions to improve patient outcomes.
Average Trading Volume: 151,874
Technical Sentiment Signal: Sell
Current Market Cap: $6.23M
For an in-depth examination of BFRI stock, go to TipRanks’ Overview page.